Article

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D Mutation

2025-09-03

Abstract excerpt

<title>Abstract</title> <p>KRAS, the most commonly mutated oncogene, plays a central role in the pathogenesis of many cancers. Identifying T cell receptors (TCRs) reactive to mutant KRAS enables the exploration of TCR gene-modified T cell (TCR-T) therapy for solid tumors with KRAS mutations. An investigator-initiated trial (IIT) evaluated adoptive TCR-T therapy using autologous T cells engineered to target KRAS G...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1dc821ae-846a-5eb4-b925-c845ebcaa24c
DOI: 10.21203/rs.3.rs-7496490/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationDOI 10.21203/rs.3.rs-7496490/v1Read

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.Semantic proximity Read

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.Semantic proximity Read

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.Semantic proximity Read

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read

KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis.Semantic proximity Read

IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V MutationSemantic proximity Read

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development.Semantic proximity Read

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read